vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and SYPRIS SOLUTIONS INC (SYPR). Click either name above to swap in a different company.
SYPRIS SOLUTIONS INC is the larger business by last-quarter revenue ($30.3M vs $16.1M, roughly 1.9× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -12.9%, a 5.1% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -9.5%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs -7.7%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Sypris Solutions Inc. is a U.S.-headquartered provider of highly engineered components and specialized technical services, primarily serving aerospace, defense, automotive and commercial industrial markets. It delivers custom manufacturing, performance testing, and value-added engineering support for mission-critical systems and parts for global enterprise clients.
DERM vs SYPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $30.3M |
| Net Profit | $-1.2M | $-3.9M |
| Gross Margin | — | 4.6% |
| Operating Margin | -2.8% | -10.9% |
| Net Margin | -7.8% | -12.9% |
| Revenue YoY | 27.3% | -9.5% |
| Net Profit YoY | -182.0% | -2992.6% |
| EPS (diluted) | $-0.04 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $30.3M | ||
| Q3 25 | $17.0M | $28.7M | ||
| Q2 25 | $15.0M | $31.4M | ||
| Q1 25 | $13.1M | $29.5M | ||
| Q4 24 | $12.6M | $33.4M | ||
| Q3 24 | $14.6M | $35.7M | ||
| Q2 24 | $14.9M | $35.5M | ||
| Q1 24 | $13.0M | $35.6M |
| Q4 25 | $-1.2M | $-3.9M | ||
| Q3 25 | $-2.3M | $517.0K | ||
| Q2 25 | $-3.8M | $-2.1M | ||
| Q1 25 | $-4.1M | $-899.0K | ||
| Q4 24 | $1.5M | $135.0K | ||
| Q3 24 | $-2.4M | $390.0K | ||
| Q2 24 | $-3.4M | $16.0K | ||
| Q1 24 | $-10.4M | $-2.2M |
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 7.2% | ||
| Q2 25 | — | 8.2% | ||
| Q1 25 | — | 11.4% | ||
| Q4 24 | 82.3% | 16.1% | ||
| Q3 24 | 63.9% | 16.8% | ||
| Q2 24 | 56.0% | 15.9% | ||
| Q1 24 | 47.7% | 8.1% |
| Q4 25 | -2.8% | -10.9% | ||
| Q3 25 | -9.0% | -6.1% | ||
| Q2 25 | -19.2% | -4.6% | ||
| Q1 25 | -25.3% | -0.4% | ||
| Q4 24 | 17.7% | 3.9% | ||
| Q3 24 | -19.8% | 4.8% | ||
| Q2 24 | -19.7% | 3.6% | ||
| Q1 24 | -77.4% | -3.9% |
| Q4 25 | -7.8% | -12.9% | ||
| Q3 25 | -13.6% | 1.8% | ||
| Q2 25 | -25.3% | -6.5% | ||
| Q1 25 | -31.0% | -3.0% | ||
| Q4 24 | 12.1% | 0.4% | ||
| Q3 24 | -16.3% | 1.1% | ||
| Q2 24 | -22.6% | 0.0% | ||
| Q1 24 | -80.1% | -6.2% |
| Q4 25 | $-0.04 | $-0.17 | ||
| Q3 25 | $-0.09 | $0.02 | ||
| Q2 25 | $-0.16 | $-0.09 | ||
| Q1 25 | $-0.18 | $-0.04 | ||
| Q4 24 | $0.10 | $0.00 | ||
| Q3 24 | $-0.12 | $0.02 | ||
| Q2 24 | $-0.17 | $0.00 | ||
| Q1 24 | $-0.53 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | — |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $17.8M |
| Total Assets | $94.6M | $107.8M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | — | ||
| Q3 25 | $24.9M | — | ||
| Q2 25 | $20.3M | — | ||
| Q1 25 | $21.1M | — | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $22.5M | — | ||
| Q2 24 | $23.9M | — | ||
| Q1 24 | $24.1M | — |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $17.8M | ||
| Q3 25 | $25.9M | $20.0M | ||
| Q2 25 | $19.2M | $18.7M | ||
| Q1 25 | $21.5M | $19.0M | ||
| Q4 24 | $20.1M | $19.6M | ||
| Q3 24 | $10.9M | $18.2M | ||
| Q2 24 | $11.3M | $19.0M | ||
| Q1 24 | $13.0M | $20.8M |
| Q4 25 | $94.6M | $107.8M | ||
| Q3 25 | $85.2M | $112.5M | ||
| Q2 25 | $81.2M | $105.8M | ||
| Q1 25 | $85.0M | $110.2M | ||
| Q4 24 | $80.2M | $119.4M | ||
| Q3 24 | $64.0M | $121.6M | ||
| Q2 24 | $65.2M | $124.2M | ||
| Q1 24 | $66.6M | $129.0M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-1.1M |
| Free Cash FlowOCF − Capex | — | $-1.5M |
| FCF MarginFCF / Revenue | — | -5.0% |
| Capex IntensityCapex / Revenue | — | 1.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-6.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-1.1M | ||
| Q3 25 | $-2.4M | $-178.0K | ||
| Q2 25 | $-942.0K | $1.1M | ||
| Q1 25 | $-2.8M | $-5.5M | ||
| Q4 24 | $2.2M | $2.3M | ||
| Q3 24 | $-1.2M | $-4.8M | ||
| Q2 24 | $-5.2M | $6.2M | ||
| Q1 24 | $-5.0M | $-1.7M |
| Q4 25 | — | $-1.5M | ||
| Q3 25 | — | $-390.0K | ||
| Q2 25 | — | $941.0K | ||
| Q1 25 | — | $-5.5M | ||
| Q4 24 | — | $1.9M | ||
| Q3 24 | — | $-4.9M | ||
| Q2 24 | — | $6.0M | ||
| Q1 24 | — | $-2.0M |
| Q4 25 | — | -5.0% | ||
| Q3 25 | — | -1.4% | ||
| Q2 25 | — | 3.0% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | -13.8% | ||
| Q2 24 | — | 16.8% | ||
| Q1 24 | — | -5.7% |
| Q4 25 | — | 1.3% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 0.4% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | 17.13× | ||
| Q3 24 | — | -12.21× | ||
| Q2 24 | — | 385.25× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
SYPR
| Sypris Electronics | $17.7M | 59% |
| Transferred At Point In Time | $12.5M | 41% |
